The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease

Rachael Bartlett1, Leanne Stokes1, Ronald Sluyter2

  • 1School of Biological Sciences, University of Wollongong, New South Wales, Australia and Illawarra Health and Medical Research Institute, Wollongong, New South Wales, Australia (R.B., R.S.); and Health Innovations Research Institute, School of Medical Sciences, RMIT University, Bundoora, Victoria, Australia (L.S.).

Insights

P2X7 receptor antagonists show promise for treating inflammatory, immune, and neurologic disorders. This review summarizes their use in preclinical models and ongoing human clinical trials, highlighting P2X7 as a therapeutic target.

Area of Science:

  • Immunology
  • Neuroscience
  • Pharmacology

Background:

  • The P2X7 receptor (P2X7) is an ATP-gated ion channel primarily on immune cells.
  • P2X7 activation influences inflammation, cell death, and proliferation, implicating it in various diseases.

Purpose of the Study:

  • This review focuses on P2X7 antagonists in preclinical models of neurologic, inflammatory, and musculoskeletal disorders.
  • It also covers P2X7 characterization, variants, signaling, and therapeutic potential.

Main Methods:

  • The review synthesizes data from rodent models of disease and injury.
  • It discusses P2X7 cloning, characterization across species, and genetic variations.
  • Emerging signaling pathways and modulators of P2X7 are also examined.

Main Results:

  • P2X7 antagonists have demonstrated efficacy in numerous rodent disease models.
  • The review details P2X7 gating, permeability, and polymorphic/splice variants.
  • Preclinical data supports P2X7's role in diverse pathological conditions.

Conclusions:

  • P2X7 antagonists are a promising therapeutic strategy for various diseases.
  • Further research into P2X7 signaling and modulators will advance its clinical application.
  • Clinical trials are underway, exploring P2X7's potential as a drug target.

Related Concept Videos

Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.6K
Non-gated Ion Channels01:24

Non-gated Ion Channels

Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
7.3K
Mechanically-gated Ion Channels01:12

Mechanically-gated Ion Channels

Mechanically-gated ion channels are proteins found in eukaryotic and prokaryotic cell membranes that open in response to mechanical stress. Tension, compression, swelling, and shear stress can alter the conformation of the protein, opening a transmembrane channel that allows the passage of ions for signal transmission. In eukaryotes, mechanically-gated channels are distributed in several regions like the neurons, lungs, skin, bladder, and heart, where they play critical roles in numerous...
6.6K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Ligand-gated Ion Channels01:19

Ligand-gated Ion Channels

Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
11.4K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K